Structural basis for the binding of high affinity phosphopeptides to Stat3

被引:28
作者
McMurray, John S. [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
Stat3; phosphopeptide; peptidomimetic; SH2; domain; molecular model;
D O I
10.1002/bip.20901
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Signal transducer and activator of transcription 3 (Stat3) is constitutively active in a number of cancers where it participates in aberrant transcription of prosurvival, cell cycling, and angiogenesis genes. Since Stat3 initiates its signaling activity through binding of its SH2 domain to phosphotyrosine residues on cell surface receptors, inhibitors targeting this region of the protein are potential chemotherapeutic agents. To date, no NMR or X-ray crystallographic structures of high-affinity phosphopeptides complexed with the Stat3 SH2 domain are available to aid in the development of peptidomimetic antagonists. Examination of the crystal structures of several STAT proteins and the complex of Stat1 with Ac-pTyr-Asp-Lys-Pro-His-NH2 led to a hypothesis that the specificity determinant for Stat3, glutamine at position pY+3 in pTyr-Xxx-Xxx-Gln sequences, resides in a unique pocket on the protein surface at the juncture of the third strand of the central beta-sheet and a unique, STAT specific alpha-helix. Docking of Ac-pTyr-Leu-Pro-Gln-NHBn to the SH2 domain of Stat3 using molecular modeling showed that the Gln binds tightly in this pocket and participates in a network of hydrogen bonds. Novel interactions between the peptide main chain and the protein were also discovered. Phosphopeptide structure-affinity studies using unnatural amino acids and glutamine derivatives provide evidence for the peptide-protein interactions revealed by the model and lend support to the binding hypothesis. (C) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:69 / 79
页数:11
相关论文
共 57 条
  • [1] ANDREWS P, 2003, PRACTICE MED CHEM, P327
  • [2] Three-dimensional structure of the Stat3β homodimer bound to DNA
    Becker, S
    Groner, B
    Müller, CW
    [J]. NATURE, 1998, 394 (6689) : 145 - 151
  • [3] STATs in oncogenesis
    Bowman, T
    Garcia, R
    Turkson, J
    Jove, R
    [J]. ONCOGENE, 2000, 19 (21) : 2474 - 2488
  • [4] Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase
    Breeze, AL
    Kara, BV
    Barratt, DG
    Anderson, M
    Smith, JC
    Luke, RW
    Best, JR
    Cartlidge, SA
    [J]. EMBO JOURNAL, 1996, 15 (14) : 3579 - 3589
  • [5] The role of STATs in transcriptional control and their impact on cellular function
    Bromberg, J
    Darnell, JE
    [J]. ONCOGENE, 2000, 19 (21) : 2468 - 2473
  • [6] Stat proteins and oncogenesis
    Bromberg, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) : 1139 - 1142
  • [7] Buettner R, 2002, CLIN CANCER RES, V8, P945
  • [8] Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
    Burke, WM
    Jin, XH
    Lin, HJ
    Huang, M
    Liu, R
    Reynolds, RK
    Lin, JY
    [J]. ONCOGENE, 2001, 20 (55) : 7925 - 7934
  • [9] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115
  • [10] Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor
    Chakraborty, A
    Dyer, KF
    Cascio, M
    Mietzner, TA
    Tweardy, DJ
    [J]. BLOOD, 1999, 93 (01) : 15 - 24